FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg
FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.
You may also be interested in...
China plans to issue electronic medical cards to 50% of its residents by the end of the year in a new commitment to overhaul the country's healthcare system and strengthen capacity to handle the sheer volume of Chinese patients
Fifty percent of the country's residents are slated to receive electronic medical cards by year's end, establishing a system that could vastly improve personalized care, comparative effectiveness research and adverse event monitoring.
An atmosphere of distrust in government makes FDA vulnerable to congressional meddling, Commissioner Margaret Hamburg suggested in a July 25 presentation to consumer group Public Citizen.